Clinical Trials
226 trialsStudy of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
University of Rochester
LungTIME-C01
Hunan Province Tumor Hospital
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
City of Hope Medical Center
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer
City of Hope Medical Center
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
Roswell Park Cancer Institute
ALCG-01
Gazi University
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
HyPeR
Royal Marsden NHS Foundation Trust
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Big Ten Cancer Research Consortium
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
PEERS
Fundación GECP
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
POTENT
Institute of Cancer Research, United Kingdom
PANDA-VAC
UNC Lineberger Comprehensive Cancer Center
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
PSI-Immune
University of Pittsburgh
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
University of Pittsburgh
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Wake Forest University Health Sciences
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
TOP 1501
Duke University
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
PNeoVCA
Mayo Clinic
ANTELOPE
Charite University, Berlin, Germany
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
NIRVANA-LUNG
UNICANCER
PECATI
MedSIR
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Providence Health & Services
EBNK-ST-001
Essen Biotech
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Emory University
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
META-1
UNICANCER
MESO-PRIME
Royal Marsden NHS Foundation Trust
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
M.D. Anderson Cancer Center
CRYOMUNE
Institut Bergonié
DoceRamPem
Emory University
PRIMING
Royal Marsden NHS Foundation Trust
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Oncomabs
Oslo University Hospital
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center